Cochrane Overview: Biologics more effective than placebo in treating rheumatoid arthritis .
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: A Cochrane overview
CMAJ. 2009 Nov 24;181(11):787-96. Epub 2009 Nov 2.This network meta-analysis identified 6 Cochrane Collaboration systematic reviews, comprised in total of 31 studies. These reviews examined the safety and benefits of 6 biologics in patients with rheumatoid arthritis (abatacept, adalimumab, anakinra, etanercept, infliximab and rituximab). The primary outcomes of this study were safety (number of withdrawals related to adverse effects) and benefit (50% improvement in reported criteria of the American College of Rheumatology [ACR50]). The biologics adalimumab and etanercept were most effective, with etanercept showing greater safety compared to the other biologics. Results of this analysis were limited by the heterogeneous population characteristics and indirect comparisons between trials.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
